Micropeptide Therapy Slows Age-Related Vascular Calcification
A newly described micropeptide can slow vascular calcification in animal models by promoting ubiquitination and degradation of PKM2. Age-related calcification occurs when vascular cells take on osteoblast-like behavior and deposit calcium phosphate, stiffening vessels and raising cardiovascular risk. Current options such as EDTA chelation offer limited benefit, so this approach is a step toward better therapies, though reversing calcification remains an unmet goal.
Age-related vascular calcification involves vascular smooth muscle cells shifting toward bone-forming behavior and depositing calcium phosphate in vessel walls. This stiffening can contribute to hypertension and, when heart structures such as aortic valves calcify, may become fatal. It also progresses alongside atherosclerosis but is described as a separate disease process.
Researchers identified a 40-amino-acid micropeptide, PKM2 AP, found at higher levels in chronic kidney disease-related calcification. It occurs in mitochondrial and cytoplasmic compartments, binds PKM2, and appears to promote PKM2 ubiquitination and degradation, slowing calcification in animal models.
If the animal findings translate, this approach could matter most for older adults and people with chronic kidney disease, who face higher calcification-related cardiovascular risk. A treatment that slows rather than reverses calcification may modestly complement existing options such as EDTA chelation, which offer limited benefit. Patients and clinicians may gain another research avenue, but near-term clinical impact remains uncertain until human trials show safety and meaningful outcomes.